Therapy of Melanoma with Allogeneic Melanoma Lysates Alone or with Interferon-Alfa

REFERENCES

• Mitchell M.S., Kan-Mitchell J., Kempf R.A., Harel W., Shau H., Lind S. Active Specific Immunotherapy of Melanoma. Phase I Trial of Allogeneic Melanoma Lysates and a Novel Adjuvant. Cancer Res. 1988; 48: 5883–5893
   PubMed Web of Science ®Google Scholar
• Mitchell M.S., Harel W., Kempf R.A., Kan-Mitchell J., Boswell W.D., Hu E., Dean G., Stevenson L. Active-Specific Immunotherapy for Melanoma. J. Clin. Oncol. 1990; 8: 856–869
   PubMed Web of Science ®Google Scholar
• Berd D., Maguire H.J., Mastrangelo M.J. Potentiation of Human Cell-Mediated and Humoral Immunity by Low-Dose Cyclophosphamide. Cancer Res. 1984; 44: 5439–5443
   PubMed Web of Science ®Google Scholar
• Morton D.L., Foshag L.J., Hoon D.S., Nizze J.A., Famatiga E., Wanek L.A., Chang C., Davtyan D.G., Gupta R.K., Elashoff R. Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy with a New Polyvalent Melanoma Vaccine [Published Erratum Appears in Ann. Surg. 1993 Mar; 217(3):309]. Ann. Surg. 1992; 216: 463–482
   PubMed Web of Science ®Google Scholar
• Mitchell M.S., Jakowatz J., Harel W., Dean G., Stevenson L., Boswell W.D., Groshen S. Increased Effectiveness of Interferon-alfa 2b Following Active Specific Immunotherapy for Melanoma. J. Clin. Oncol. 1994; 12: 402–411
   PubMed Web of Science ®Google Scholar
• Elliott G.T., McLeod R.A., Perez J., Von Eschen K.B. Interim Results of a Phase II Multicenter Clinical Trial Evaluating the Activity of a Therapeutic Melanoma Vaccine (Theraccine) in the Treatment of Disseminated Malignant Melanoma. Semin. Surg. Oncol. 1993; 9: 264–272
   PubMed Web of Science ®Google Scholar
• Hersey P. Vaccinia Viral Lysates in Treatment of Melanoma. Biological Approaches to Cancer Treatment: Biomodulation, M.S. Mitchell. McGraw-Hill, New York 1992; 302–325
   Google Scholar
• Kirkwood J.M., Ernstoff M.E. Potential Applications of the Interferons in Oncology. Semin. Oncol. 1986; 13: 48–56
   PubMed Web of Science ®Google Scholar
• Mitchell M.S. Perspective on Allogeneic Melanoma Lysates in Active Specific Immunotherapy. Semin. Oncol. 1998; 25: 623–635
   PubMed Web of Science ®Google Scholar
• Mitchell M.S., Harel W., Kempf R.A., Kan-Mitchell J., Boswell W.D., Hu E., Dean G., Stevenson L. Active-Specific Immunotherapy for Melanoma. J. Clin. Oncol. 1990; 8: 856–869
   PubMed Web of Science ®Google Scholar
• Mitchell M.S., Harel W., Kan-Mitchell J., LeMay L.G., Goedegebuure P., Huang X.-Q., Hofman F., Groshen S. Active Specific Immunotherapy of Melanoma with Allogeneic Cell Lysates: Rationale, Results and Possible Mechanisms of Action. Specific Immunotherapy of Cancer with Vaccines, J.-C. Bystryn, S. Ferrone. Ann. N.Y. Acad. Sci. 1993; 153–166
   Google Scholar
• Kan-Mitchell J., Huang X.-Q., Steinman L., Oksenberg J.R., Harel W., Parker J.W., Goedegebuure P., Darrow T.L., Mitchell M.S. Clonal Analysis of In Vitro-Activated CD8+ Cytotoxic T Lymphocytes from a Melanoma Patient Responsive to Active Specific Immunotherapy. Cancer Immunol. Immunother. 1993; 37: 15–25
   PubMed Web of Science ®Google Scholar
• Huang X.-Q., Mitchell M.S., Liggett P.E., Murphree A.L., Kan-Mitchell J. Non-fastidious, Melanoma-Specific CD8+Cytotoxic T Lymphocytes from Choroidal Melanoma Patients. Cancer Immunol. Immunother. 1994; 38: 399–405
   PubMed Web of Science ®Google Scholar
• LeMay L.G., Kan-Mitchell J., Goedegebuure P., Harel W., Mitchell M.S. Detection of Human Melanoma-Reactive CD4+ HLA Class I-Restricted Cytotoxic T Cell Clones with Long-Term Assay and Pretreatment of Targets with Interferon-Gamma. Cancer Immunol. Immunother. 1993; 37: 187–194
   PubMed Web of Science ®Google Scholar
• Goedegebuure P., Harel W., LeMay L.G., Kan-Mitchell J., Mitchell M.S. Cytotoxic CD4+ Lymphocyte Clones Reactive with Melanoma: The Role of HLA and Accessory Molecules. Vaccine Res. 1994; 2: 249–261
   Google Scholar
• Mitchell M.S., Harel W., Groshen S. Association of HLA Phenotype with Clinical Response to Active Specific Immunotherapy of Melanoma. J. Clin. Oncol. 1992; 10: 1158–1168
   PubMed Web of Science ®Google Scholar
• Hutchins J.T., Deans R.J., Mitchell M.S., Uchiyama C., Kan-Mitchell J. Novel Gene Sequences Expressed by Human Melanoma Cells Identified by Molecular Subtraction. Cancer Res. 1991; 51: 1418–1425
   PubMed Web of Science ®Google Scholar
• Weiler S.R., Taylor S.M., Deans R.J., Kan-Mitchell J., Mitchell M.S., Trent J.M. Assignment of a Human Melanoma Associated Gene MG50 (D2S448) to Chromosome 2p25.3 by Fluorescence In Situ Hybridization. Genomics 1994; 22: 243–244
   PubMed Web of Science ®Google Scholar
• Mitchell M.S., Kan-Mitchell J., Minev B., Edman C., Deans R.J. A Novel Melanoma Gene (MG50) Encoding the Interleukin 1 Receptor Antagonist and Six Epitopes Recognized by Human Cytolytic T Lymphocytes. Cancer Res. 2000; 60: 6448–6456
   PubMed Web of Science ®Google Scholar
• Nestle F.O., Alijagic S., Gilliet M., Sun M., Grabbe S., Dummer R., Burg G., Schadendorf D. Vaccination of Melanoma Patients with Peptide—or Tumor Lysate—Pulsed Dendritic Cells. Nat. Med. 1998; 4: 328–332
   PubMed Web of Science ®Google Scholar
• Sosman J.A., Unger J.M., Liu P.Y., Flaherty L.E., Park M.S., Keupf R.A., Thompson J.A., Terasaki P.I., Sondak V.K. Adjuvant Immunotherapy of Resected, Intermediate Thickness Node-Negative Melanoma with an Allogeneic Tumor Vaccine: Impact on HLA Class 1 Antigen Expression on Outcome. Clin. Oncol. 2002; 20: 2067–2075
   Web of Science ®Google Scholar